Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept/rinucumab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Aflibercept/rinucumab - Regeneron Pharmaceuticals

Alternative Names: Aflibercept/REGN 2176; Eylea/REGN-2176; Eylea/rinucumab; PDGFR-beta-Eylea combination therapy - Bayer/Regeneron; REGN-2176-3; REGN-2176/aflibercept; REGN-2176/Eylea; Rinucumab/aflibercept; Rinucumab/Eylea

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Wet age-related macular degeneration

Most Recent Events

  • 16 Feb 2017 Regeneron Pharmaceuticals terminates a phase II trial in Wet age related macular degeneration (In Adults, In the elderly) in USA and Japan (NCT02418754)
  • 01 Dec 2016 Discontinued - Phase-II for Wet age-related macular degeneration (In the elderly, In adults) in USA, Japan (Intravitreous)
  • 30 Sep 2016 Top-line efficacy and safety data from a phase II trial in Wet age-related macular degeneration released by Regeneron Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top